drugset / Trial / NCT02303002
Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a safety and efficacy study of botulinum toxin type A in subjects with glabellar frown lines.
Timeline
- Start
- 2014-12
- Primary completion
- 2015-12
- Completion
- 2016-01
Publications
- Bertucci V, Humphrey S, Carruthers J, Solish N, Muhn C, Swift A, Rubio RG, Shears G, Rosen N. Comparing Injectable DaxibotulinumtoxinA and OnabotulinumtoxinA in Moderate and Severe Glabellar Lines: Additional Analyses From a Phase 2, Randomized, Dose-Ranging, Double-Blind, Multicenter Study. Dermatol Surg. 2017 Dec;43 Suppl 3:S262-S273. doi: 10.1097/DSS.0000000000001364.
- Carruthers J, Solish N, Humphrey S, Rosen N, Muhn C, Bertucci V, Swift A, Metelitsa A, Rubio RG, Waugh J, Quiring J, Shears G, Carruthers A. Injectable DaxibotulinumtoxinA for the Treatment of Glabellar Lines: A Phase 2, Randomized, Dose-Ranging, Double-Blind, Multicenter Comparison With OnabotulinumtoxinA and Placebo. Dermatol Surg. 2017 Nov;43(11):1321-1331. doi: 10.1097/DSS.0000000000001206.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Botulinum toxin type A | Protein / enzyme biologic | 20 iu | Intramuscular |
| Comparator | Botulinum toxin type A | Protein / enzyme biologic | 40 iu | Intramuscular |
| Comparator | Botulinum toxin type A | Protein / enzyme biologic | 60 iu | Intramuscular |
Indications
No indication recorded.